Tumor Necrosis Factor Ligand Superfamily Member 5
Tumor Necrosis Factor Ligand Superfamily Member 5 Uses, Dosage, Side Effects, Food Interaction and all others data.
Tumor Necrosis Factor Ligand Superfamily Member 5 is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
Trade Name | Tumor Necrosis Factor Ligand Superfamily Member 5 |
Generic | Dapirolizumab pegol |
Dapirolizumab pegol Other Names | Dapirolizumab pegol, Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
![Tumor Necrosis Factor Ligand Superfamily Member 5 Tumor Necrosis Factor Ligand Superfamily Member 5](https://www.medicinesfaq.com/media/png/tumor-necrosis-factor-ligand-superfamily-member-5.png)
Innovators Monograph
You find simplified version here Tumor Necrosis Factor Ligand Superfamily Member 5